Status:
COMPLETED
Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Covid-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Recent data from some of the earliest and worst affected countries of COVID-19 suggest a major overrepresentation of hypertension and diabetes among COVID-19-related deaths and among patients experien...
Eligibility Criteria
Inclusion
- Group A and B
- Verified COVID-19
- Hospital admitted
- Daily administration of RAS-inhibiting therapy
- Age 18 years and above
- Informed consent
Exclusion
- Diagnosed with systolic heart failure (heart failure with reduced ejection fraction)
- Severe kidney disease; defined by estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73 m2
- Severe hypertension; defined by systolic pressure \>175 mm Hg and/or diastolic pressure \>105 mm Hg
- Hypotension; defined by systolic pressure \<100 mm Hg and/or diastolic pressure \<60 mm Hg
- Non-compliance of RAS-inhibiting therapy; defined as an estimated adherence \<80% assessed by a questionnaire in combination with checking the Danish electronic medication system "FMK" (obligatory for clinicians in Denmark to ensure the Danish electronic medication system "FMK" is correct and up-to-date) for redeemed prescriptions in the last six months; in borderline cases, the participant is assumed compatible
- Pregnancy or breastfeeding
- Contra indications for receiving ACE inhibitors or ARBs:
- Severe liver disease
- Hypersensitivity or allergic reactions to the therapy
- Angioneurotic edema during previous treatments
- Family history of or previous idiopathic angioneurotic edema
- Treatment with sacubitril/valsartan or aliskiren
- Group C and D:
- Inclusion Criteria:
- Daily administration of RAS-inhibiting therapy
- Age 18 years and above
- Informed consent
Key Trial Info
Start Date :
May 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2022
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT04351581
Start Date
May 18 2020
End Date
December 22 2022
Last Update
January 18 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Gentofte Hospital, University of Copenhagen
Hellerup, Capital Region of Denmark, Denmark, 2900
2
Department of Medicine, Herlev Hospital, University of Copenhagen
Herlev, Capital Region of Denmark, Denmark, 2730